NETRI develops disruptive technologies to improve healthcare pathway for patients suffering from neurological troubles.
NETRI uses the organ-on-a-chip approach to develop treatments for neurological disorders.
We focuse on our internal R&D to understand how neurodegenerative diseases, treatments and chemicals affect the human brain. We investigate ex vivo complex neuronal architectures that model human brain circuits.
Once validated, neurofluidic chips are directly accessible to academia, pharmaceutical industry or biotechnological companies for their research.
We believe in ideas that can be turned into proof of concept and real products.
High throughput microfluidic devices for
in vitro drug discovery in neuroscience
SAS au capital de 1 331 € immatriculée au R.C.S de Lyon sous le n° 840 248 744
email@example.com – +33487628118
Site hébergé par Online, 8 rue de la Ville l’Evêque, 75008 Paris, +33 (0)1 84 13 00 00